(Update on Disclosed Matter) Notice Regarding Transfer of Generic Drug Business
Filed with TSE · · 6 pages · English
KYORIN Pharmaceutical Co.,Ltd. on 6ix
Earlier from KYORIN Pharmaceutical Co.,Ltd
- KYORIN to Commence Promotion Activities for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%
- [Summary]Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP]
- KYORIN Entered into Joint Marketing Agreement in Japan for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%
- KYORIN Pharmaceutical: Operating profit fell 71.6% year-over-year as sales declined and R&D costs rose
- Kyorin Pharmaceutical Co Ltd - Kyorin Enters Into License Agreement With Biodol For Novel Neuropathic Pain Treatment
Later from KYORIN Pharmaceutical Co.,Ltd
- Notice Concerning Change in Major Shareholder
- Consolidated Financial Results for Second Quarter of FY2026 - Supplementary Information
- KYORIN and Edesa Biotech Enter into License Agreement for EB05 for ARDS (Acute Respiratory Distress Syndrome)
- Notice Regarding Difference Between Financial Forecast and Actual Results and Revision
- [Summary]Consolidated Financial Results for the Six Months Ended September 30, 2026 [Japanese GAAP]
Follow KYORIN Pharmaceutical Co.,Ltd into a list and get an email when it puts out news.
Follow KYORIN Pharmaceutical Co.,Ltd